Cargando…
Pembrolizumab-Induced Myasthenia Gravis and Peripheral Neuropathy: A Case Series
Pembrolizumab is a monoclonal antibody that targets the programmed cell death protein 1 (PD-1) receptor on T-cells, thereby enhancing the antitumor immune response. Pembrolizumab has been shown to improve survival in various cancers, but it can also cause immune-related adverse events (irAEs), which...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Cureus
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10558814/ https://www.ncbi.nlm.nih.gov/pubmed/37809208 http://dx.doi.org/10.7759/cureus.44799 |